Evaluation of Xiaoaiping Combined with Oxaliplatin and Capecitabine in the Treatment of Advanced Metastatic Gastric Adenocarcinoma
Ye Xu （ Yankuang Group New Mileage General Hospital, Zoucheng City 273500, Shandong, China ）
Zhong-Feng Li （ Yankuang Group New Mileage General Hospital, Zoucheng City 273500, Shandong, China ）
Min Meng （ Yankuang Group New Mileage General Hospital, Zoucheng City 273500, Shandong, China ）
https://doi.org/10.37155/2717-5278-0101-2Abstract
Objectives: To evaluate the effect of Xiaoaiping combined with oxaliplatin and capecitabine in the treatment of advanced metastatic gastric adenocarcinoma. Methods: Seventy patients with advanced metastatic gastric adenocarcinoma in our hospital from January 2018 to March 2019 were randomly divided into the control group treated with oxaliplatin and capecitabine chemotherapy and the observation group treated with Xiaoaiping. Each group has 35 cases. The short-term efficacy of the two groups was compared. Results: The total effective rate and disease control rate of the observation group were higher than that of the control group. After treatment, tumor markers, vascular endothelial growth factors and inflammatory cytokines were lower than those in the control group. The quality of life score and peripheral lymphocyte subgroup were higher than the control group. The difference was statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusions: Xiaoaiping combined with oxaliplatin and capecitabine is effective in the treatment of advanced metastatic gastric adenocarcinoma. It's worth popularizing.
Keywords
Advanced metastatic gastric adenocarcinoma; Xiaoaiping; oxaliplatin; capecitabineFull Text
PDFReferences
[2]Zhang WQ, Zhang HH. Effect of laparoscope assisted D2 radical resection combined with enhanced recovery after surgery concept on the short-term prognosis of patients with advanced gastric cancer. China J Endoscopy 2018,24(8):67-72.
[3]Wang Q, Zhou JP, Gui D, Dong C, Zhang DC, Tang L. Comparison of efficacy and safety between SOX regimen and PF regimen as adjuvant chemotherapy for adenocarcinoma of esophagogastric junction. Anhui Med Pharm J 2017,21(2):364-367.
[4]Chen JJ, Yang J, Shi MZ, Zhang XQ, Zhang JX, Qi MJ, Han YL. Effect and Mechanism of Xiaoaiping Injection Combined Paclitaxel Inhibiting Proliferation of Breast Cancer MCF-7 Cells. Chin Arch Tradit Chin Med 2019,37(2):296-300+11-13.
[5]Ren ZL, Zhang RX, Wu XX. Clinical trial of capecitabine combined with oxaliplatin in the treatment of advanced oesphago-gastric junction adenocarcinoma. Chin J Clin Pharmacol 2016,32(12):1088-1090.
[6]Lin JR, Zhuang YZ, Wang WF, Li LY, Wen ZH, Huang JS, Xu MM. Efficacy analysis of neoadjuvant chemotherapy for resectable locally advanced adenocarcinoma of the esophageal-gastric junction. Chin J Dig Surg 2018,17(6):619-625.
[7]Li G, Liu HX, Liu J. The efficacy and safety of hyperthermic intraperitoneal chemotherapy by Los platinum and Oxaliplatin for peritoneal metastasis of gastric adenocarcinoma. Chin J Gastroenterolo Hepatol 2017,26(3):266-270.
[8]Fu YJ. Effect of oxaliplatin combined with capecitabine on advanced esophagogastric junction adenocarcinoma and its effect on serum tumor markers. Heilongjiang Med J 2018,31(3):581-583.
[9]Huang LP, Lu B, Qu CP, Geng XR, Chen ZY. Application of neoadjuvant chemotherapy in the treatment of locally advanced esophagogastric junction adenocarcinoma. Chin Arch Gen Surg (Electronic Edition) 2017,11(5):322-326.
[10]Yan X, Zhang QX, Li P, Qu FJ. Efficacy and safety of xiaoaiping combined with XELOX regimen chemotherapy in the treatment of advanced metastatic gastric adenocarcinoma. Chin J Postgrad Med 2018,41(5):413-417.
Copyright © 2019 Ye Xu, Zhong-Feng Li, Min Meng
Publishing time:2019-12-31
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location